| 1 |
35482061 | Effect of bisphosphonates on selected markers of bone turnover in patients after total knee arthroplasty. | 2022 Jul |
1 |
| 2 |
33183068 | Treatment of osteoporosis with a modified zeolite shows beneficial effects in an osteoporotic rat model and a human clinical trial. | 2021 Mar |
1 |
| 3 |
34279472 | Comparison of the Effect of Oral Versus Intravenous Bisphosphonate Administration on Osteoclastogenesis in Advanced-Stage Medication-Related Osteonecrosis of the Jaw Patients. | 2021 Jul 4 |
1 |
| 4 |
34347277 | Effect of Human Umbilical Cord Matrix-Derived Mesenchymal Stem Cells on Bisphosphonate-Related Osteonecrosis of the Jaw. | 2021 Dec |
1 |
| 5 |
31606424 | Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases. | 2020 Feb |
1 |
| 6 |
33374546 | Bisphosphonates Reduce Smoking-Induced Osteoporotic-Like Alterations by Regulating RANKL/OPG in an Osteoblast and Osteoclast Co-Culture Model. | 2020 Dec 23 |
3 |
| 7 |
30949254 | Imaging modalities for drug-related osteonecrosis of the jaw (2), Overview of the position paper on medication-related osteonecrosis of the jaw and the current status of the MRONJ in Japan. | 2019 Nov |
4 |
| 8 |
30231385 | Bones in Multiple Myeloma: Imaging and Therapy. | 2018 May 23 |
1 |
| 9 |
28367895 | Effect of bisphosphonate as an adjunct treatment for chronic periodontitis on gingival crevicuar fluid levels of nuclear factor-κB ligand (RANKL) and osteoprotegerin in postmenopausal osteoporosis. | 2017 |
1 |
| 10 |
26856585 | Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α. | 2016 Jul |
1 |
| 11 |
28228794 | Prompt clinical and biochemical response to denosumab in a young adult patient with craniofacial fibrous dysplasia. | 2016 Sep-Dec |
1 |
| 12 |
25055746 | Mechanical loading influences the effects of bisphosphonates on human periodontal ligament fibroblasts. | 2015 Apr |
1 |
| 13 |
25820558 | RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjects. | 2015 Feb 3 |
2 |
| 14 |
26337218 | Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics. | 2015 Nov |
2 |
| 15 |
26614482 | The effect of bisphosphonate treatment on the biochemical and cellular events during bone remodelling in response to microinjury stimulation. | 2015 Nov 27 |
1 |
| 16 |
27095621 | Effect of Bisphosphonates on the Levels of Rankl and Opg in Gingival Crevicular Fluid of Patients With Periodontal Disease and Post-menopausal Osteoporosis. | 2015 Dec |
2 |
| 17 |
24443409 | Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL. | 2014 Jun |
1 |
| 18 |
24982847 | Targeted treatments of bone metastases in patients with lung cancer. | 2014 |
1 |
| 19 |
25173134 | Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-κB ligand antibody in mice. | 2014 Nov |
2 |
| 20 |
25274386 | [New therapy approaches for giant cell tumors]. | 2014 Oct |
1 |
| 21 |
22901640 | Review of current literature and implications of RANKL inhibitors for oral health care providers. | 2013 Dec |
2 |
| 22 |
23212591 | Bone homeostasis and breast cancer: implications for complex therapy and the maintenance of bone integrity. | 2013 Jan |
2 |
| 23 |
24370033 | [Effect of bortezomib combined with bisphosphonates on bone metabolism index in multiple myeloma]. | 2013 Dec |
2 |
| 24 |
20938793 | Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. | 2012 Feb |
7 |
| 25 |
19574937 | Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis. | 2010 Jan-Feb |
1 |
| 26 |
19836866 | Osteonecrosis of the jaws induced by anti-RANK ligand therapy. | 2010 Apr |
2 |
| 27 |
20506157 | The increased expression of receptor activator of nuclear-kappaB ligand (RANKL) of multiple myeloma bone marrow stromal cells is inhibited by the bisphosphonate ibandronate. | 2010 Sep 1 |
3 |
| 28 |
19360288 | Examination of the mechanisms of osteolysis in patients with metastatic breast cancer. | 2009 May |
1 |
| 29 |
18260178 | Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. | 2008 Mar |
1 |
| 30 |
15670755 | Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. | 2005 Mar 4 |
1 |
| 31 |
16101188 | Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients. | 2005 Sep-Oct |
1 |
| 32 |
16393773 | The inhibitory effect of bisphosphonates on glucocorticoid-induced RANKL expression in human cells. | 2005 Nov-Dec |
5 |
| 33 |
14753746 | The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). | 2004 Jan |
2 |
| 34 |
12732166 | Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. | 2003 May |
1 |